Guardant Health SEC Filings

Insider stock changes at Guardant Health (GH): On 09/15/2025 Chief Information Officer Kumud Kalia had 638 restricted stock units vest, resulting in 638 shares issued to her and retained 324 shares that were sold to satisfy tax withholding at a price of $54.79 per share. After these transactions Kalia beneficially owns 19,488 shares of Common Stock. The Form 4 was signed by an attorney-in-fact on 09/17/2025.

Chris Freeman, Chief Commercial Officer of Guardant Health (GH), reported insider transactions dated 09/15/2025. The filing shows 1,402 restricted stock units vested and were treated as an acquisition at $0, increasing his beneficial ownership to 50,223 shares before subsequent disposition. The company retained 1,402 shares to satisfy tax withholding related to the vesting. Separately, Freeman disposed of 594 shares at $54.79, leaving him with 49,629 shares beneficially owned after the reported transactions.

Craig Eagle, Chief Medical Officer of Guardant Health, reported transactions on 09/15/2025 related to the vesting of restricted stock units (RSUs) granted June 9, 2023. A tranche of 1,402 shares vested and were delivered at no cash price to the reporting person. To satisfy tax withholding obligations, the company retained 711 shares at an effective withholding price of $54.79 per share.

After these transactions the reporting person beneficially owned 37,482 shares of Guardant Health common stock. The RSU award vests over three years (33% vested June 15, 2024; remaining 67% vests in equal quarterly installments over the following two years). The Form 4 was signed by an attorney-in-fact on 09/17/2025.

Michael Brian Bell, Chief Financial Officer of Guardant Health, reported changes in his beneficial ownership on 09/15/2025. He received two installments of restricted stock units that resulted in 1,233 and 2,039 common shares being issued (transaction codes M) and the company retained 1,233 shares to cover tax withholding. He sold 1,659 shares at $54.79 (transaction code F). Following these transactions he beneficially owned 46,300 shares.

Guardant Health, Inc. (GH) Form 144 reports a proposed sale of 26 common shares by a person associated with the issuer, to be executed approximately on 09/17/2025 through Charles Schwab & Co., Inc. The shares arose from a restricted stock lapse on 09/15/2025 and were issued as equity compensation. The filing lists 26 shares outstanding to be sold with an aggregate market value shown as $1,446.00 and total company shares outstanding at 124,705,857. The form also discloses three prior small sales by the same seller of 26 shares each on 06/18/2025, 07/17/2025, and 08/19/2025 with gross proceeds of $1,286, $1,253, and $1,535 respectively.

Form 144 notice for Guardant Health, Inc. (GH) shows an intended sale of 116 common shares via Charles Schwab on 09/17/2025 with an aggregate market value of $6,453. The shares were acquired on 09/15/2025 through a restricted stock lapse under equity compensation. The filing lists prior open-market sales by the same account in the past three months: 3,213 shares for $158,947 on 06/18/2025, and two smaller sales of 116 shares$5,591 and $6,846 on 07/17/2025 and 08/19/2025, respectively. The signer affirms no undisclosed material adverse information.

Helmy Eltoukhy, Co-CEO and director of Guardant Health (GH), filed a Form 4 reporting open-market sales of the company’s common stock on 09/09/2025. The filing shows two sale transactions: 294,723 shares sold at a weighted average price of $59.4447 and 5,277 shares sold at a weighted average price of $59.9346. After these sales the reported beneficial ownership was 2,128,776 shares and 2,123,499 shares, respectively. Footnotes state the larger block sold at prices ranging from $58.79 to $59.78 and the smaller block from $59.79 to $60.25, with a weighted average reported for each block.

The Form 4 is signed by an attorney-in-fact on behalf of Mr. Eltoukhy and contains no additional commentary, option transactions, or other derivative activity.

Guardant Health, Inc. (GH) filed a Form 144 to notify a proposed sale of securities under Rule 144. The filing states that 300,000 shares of Common Stock are to be sold through Stifel Nicolaus & Company Inc. on or about 09/09/2025 on Nasdaq, with an aggregate market value of $17,835,990.00. The filer reports acquisition details for the shares: 286,065 shares from Restricted Stock Units acquired 01/07/2021 and 50,000 shares purchased on 11/19/2021, with cash noted as the payment method. The filer certifies no undisclosed material adverse information and provides the standard Rule 144 attestation.